|
|
|
Clinical Research Detail |
|
|
|
Title Of Study |
A phase III, double-blind, placebo-controlled extension trial to investigate the long-term efficacy and safety of low (50 mg/day) and high (100 mg/day) dose safinamide, as add-on therapy in subjects with early idiopathic Parkinson`s disease treated with a stable dose of a single dopamine agonist.
|
|
|
Disease Condition |
Idiopathic Parkinson`s Disease
|
|
|
Phase of Trial |
Phase-3
|
Discipline |
Neurology
|
|
|
Start date of Trial |
9/28/2009
|
Closing Date of Trial |
11/28/2012
|
|
|
|